The aims of the present study is to examine whether Time-Restricted Feeding (TRF) is a safe and effective regimen to improve insulin resistance and decrease body weight in overweight/obese Polycystic ovary syndrome (PCOS) patients over 16 weeks compared to reduced energy restriction.
Intermittent fasting regimens involve periods fasting followed by periods of eating freely. Time-Restricted Feeding (TRF) is a new form of intermittent fasting and involves shortening the eating window to 4-10 h/day. TRF is a safe lifestyle intervention for weight loss in adults with obesity. Accumulating evidence suggests that TRF is an effective means of decreasing body weight and improving insulin resistance but did not have any negative impact on eating disorder symptoms, body image perception, or eating behaviors. Polycystic ovary syndrome (PCOS) is the most common endocrine condition in productive-aged women. About 60-70 % of women with PCOS are obese or overweight, and obesity is associated with insulin resistance. Since many women with PCOS seem to have insulin resistance, compensatory hyperinsulinemia is thought to contribute to hyperandrogenism by direct stimulation of ovarian production of androgens and by inhibition of liver synthesis of SHGB. It is important to ameliorate insulin resistance in PCOS patients.The aims of the present study is to examine whether TRF is a safe and effective regimen to improve insulin resistance and decrease body weight in overweight/obese PCOS patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
93
Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
Participants receive a general lifestyle counseling.
The first afilliated hospital of Xiamen university
Xiamen, Fujian, China
Changes in body weight (Kilograms)
Changes in body weight (Kilograms)
Time frame: Baseline and 16 weeks
Change in insulin resistance
Insulin resistance will be assessed by HOMA-IR
Time frame: Baseline and 16 weeks
Change in BMI
Time frame: Baseline and 16 weeks
Changes in waist circumference (cm)
Time frame: Baseline and 16 weeks
Changes in Waist-to-Hip Ratio(WHR)
Time frame: Baseline and 16 weeks
Changes in systolic pressure(SBP)
Time frame: Baseline and 16 weeks
Changes in diastolic pressure (DBP)
Time frame: Baseline and 16 weeks
Change in Body fat percent
Time frame: Baseline and 16 weeks
Change in Fat mass
Time frame: Baseline and 16 weeks
Change in Skeletal muscle mass
Time frame: Baseline and 16 weeks
Change in CHO level
Time frame: Baseline and 16 weeks
Change in TG level
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline and 16 weeks
Change in HDL level
Time frame: Baseline and 16 weeks
Change in LDL-c level
Time frame: Baseline and 16 weeks
Change in Fasting Blood Glucose (FBG) level
Time frame: Baseline and 16 weeks
Change in ALT level
Time frame: Baseline and 16 weeks
Change in AST level
Time frame: Baseline and 16 weeks
Change in GGT level
Time frame: Baseline and 16 weeks
Change in Testosterone level
Time frame: Baseline and 16 weeks
Change in Sex hormone binding globulin (SHBG) level
Time frame: baseline and 16 weeks
Change in Free androgen index (FAI)
Time frame: Basline and 16 weeks
Change in Ferriman-Gallway score (F-G score:)
Time frame: Baseline and 16 weeks